Patents by Inventor Stephen Philip Keen

Stephen Philip Keen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF
    Publication number: 20210154221
    Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. The present invention also provides processes for the preparation of 4?-substituted nucleoside derivatives of Formula I and derivatives thereof.
    Type: Application
    Filed: February 3, 2021
    Publication date: May 27, 2021
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Limited
    Inventors: Mark McLaughlin, Edward Cleator, Jongrock Kong, Andrew William Gibson, David R. Lieberman, Alejandro Diequez Vazquez, Stephen Philip Keen, Michael J. Williams, Jeffrey C. Moore, Erika M. Milczek, Feng Peng, Kevin M. Belyk, Zhiguo Jake Song
  • 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF
    Publication number: 20190022115
    Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula (I) and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. The present invention also provides processes for the preparation of 4?-substituted nucleoside derivatives of Formula (I) and derivatives thereof.
    Type: Application
    Filed: September 16, 2016
    Publication date: January 24, 2019
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Limited
    Inventors: Vinay M. Girijavallabhan, Mark McLaughlin, Edward Cleator, Jongrock Kong, Andrew William Gibson, David R. Lieberman, Alejandro Dieguez Vazquez, Stephen Philip Keen, Michael J. Williams, Jeffrey C. Moore, Erika M. Milczek, Feng Peng, Kevin M. Belyk, Zhiguo Jake Song
  • Enantioselective synthesis of 13-oxotricyclo[8.2.1.0.] trideca-3(8),4,6-triene-5-carboxylates
    Patent number: 7759492
    Abstract: An enantioselective route to compounds of formula I is disclosed: The compounds of formula I are key intermediates in the synthesis of compounds useful in treatment of Alzheimer's disease.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: July 20, 2010
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Stephen Philip Keen, Steven Fraser Oliver, Gavin William Stewart
  • ? v integrin receptor antagonists
    Patent number: 7288655
    Abstract: The present invention relates to the synthesis of intermediates for the preparation of compounds of formula (A): wherein n is 2 or 3 and various salt forms of these compounds.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: October 30, 2007
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Ltd.
    Inventors: Brian Christopher Bishop, Karel Marie Joseph Brands, Ian Frank Cottrell, Cameron John Cowden, Antony John Davies, Stephen Philip Keen, David Ross Lieberman, Gavin William Stewart